Close menu




June 9th, 2022 | 13:32 CEST

Where strong brands meet good concepts: Apple, Pathfinder Ventures, Deutsche Bank

  • Digitization
  • Camping
  • Investments
Photo credits: pixabay.com

When technology giant Apple unveils something new, it is still something of a happening. Recently, the new M2 chip for Macbooks was launched. Its promise: faster computing power, short memory access times and advantages in AI applications. It is good news for Apple fans - after all, applications around graphics and video are particularly demanding and require powerful hardware. But Apple is more than a hardware supplier: iTunes is indispensable for many users and remains an essential foundation for Apple's success. We present other stocks that could be on the verge of a boost thanks to digitization and strong brands.

time to read: 3 minutes | Author: Nico Popp
ISIN: APPLE INC. | US0378331005 , PATHFINDER VENTURES INC | CA70323P1071 , DEUTSCHE BANK AG NA O.N. | DE0005140008

Table of contents:


    Apple: An ecosystem for future profits

    But what is the actual state of Apple? Is the share of the jack-of-all-trades no longer promising? The regular innovations from Cupertino also lead to steady sales. If you are a true Apple fan, you simply treat yourself to the better processor or, the more powerful smartphone. In addition, Apple is well-positioned in terms of digital content, and users buy music and movies from iTunes as a matter of course. Twenty years ago, things looked very different. Back then, anyone who wanted to sell music digitally had a hard time because of the numerous illegal alternatives. Today, it is quite normal to buy music. The reason for this is the ecosystems in which customers operate. Apple has created an ecosystem that will continue to generate revenue for many years to come. The stock is currently lagging behind other tech stocks, but this can become an opportunity in the medium term. In the short term, however, there is no need for action.

    Pathfinder Ventures: Camping for families - Every good concept has a beginning

    One company that is just starting to build its ecosystem for future revenue is Pathfinder Ventures. The operator of campgrounds with a focus on RVs launched in 2019 ahead of the pandemic to buy up some previously family-run sites and digitize booking processes and other service offerings. One of the Company's focuses is on family-friendly sites that are located in scenic areas and also offer recreational activities. Another mainstay of Pathfinder Ventures is RV parking. Since Pathfinder operates campgrounds in Canada in the District of British Columbia, sometimes only a few kilometers from major cities, there are not only permanent campers but also weekend guests who want to park their "Recreation Vehicle" (RV) on-site.

    Currently, Pathfinder Ventures operates three RV parks and has its sights set on other potential acquisition targets. Since the market for campgrounds in Canada and the US is very fragmented, and there is an obvious digitalization deficit in terms of marketing and service, the team around founder and camping fan Joe Bleackley expects synergy effects and growth potential from further acquisitions. Families, in particular, rely on modern equipment, leisure activities, digital services, and quiet sites and should thus become regular guests of Pathfinder. The Company's goal is to become a reliable brand that offers consistent standards for a lucrative target group. Already, a round trip through all of Pathfinder's parks through British Columbia and Vancouver Island is an option. In addition to guests from Canada, tourists from Europe could also play a growing role for Pathfinder Ventures in the long term. The Company is currently valued at EUR 4.6 million. Besides billion-dollar companies such as Sun Communities or Equity Lifestyle Properties, it is the only smallcap in the RV vacation and camping sector.

    Deutsche Bank: Share does not get going

    A relaxing few weeks in a mobile home in Canada should also be good for leading Deutsche Bank employees - if the public prosecutor's office doesn't call in between. Although only the fund subsidiary DWS was recently affected, the frequent activities of the authorities in the Frankfurt bank towers are noticeable. Otherwise, things are not going badly for Deutsche Bank. The prospect of rising interest rates, also in Europe, gives hope to the lending business. Coupled with the digitalization of recent years, Deutsche Bank could play a more vital role in the market again in the medium term. Perhaps the pressure to generate returns in other areas at any price will then also fade. Despite the good prospects, the share is not really gaining momentum. The pressure to act looks different.


    While shares like Deutsche Bank, with the efficiency gains of recent years still not falling on fertile ground, even though the turnaround in interest rates is already underway, the potential at Apple seems to have been exhausted to some extent. Nevertheless, the Company from Cupertino has great potential - every new product that the corporation can successfully integrate into its ecosystem is likely to be a success. Similarly, the camping park operator Pathfinder Ventures could also succeed. Digital infrastructure and consistent quality for families is a compelling concept. More parks and the story could become a no-brainer. The story is at the beginning, but that is precisely why it is worth following closely!


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read